Principal Investigator: Deepa Suryanarayan
Funding: CanVECTOR Pilot
Design: Open-label pilot RCT(randomized clinical trial) comparing Apixaban and current standard of care with LMWH (low-molecular-weight heparin) for treatment of catheter-related thrombosis in patients with cancer.
Principal Investigators: Kerstin de Wit
Co-Investigators:
Lana Castellucci and Marc Rodger (Ottawa)
Ali Mulla
Sudeep Shivakumar (Halifax)
Andrew Hirsch and Susan Kahn (Montreal)
Funding: CanVECTOR Pilot
Design: Prospective cohort study of patients on warfarin or DOAC for at least 3 months who require cessation of anticoagulation for a planned elective procedure.
Principal Investigator: Michael Kovacs
Funding: BMS Pfizer (Bristol-Myers Squibb Pfizer)
Design: Prospective observational cohort of patients on Warfarin or DOAC (Direct Oral Anticoagulant) for at least 3 months who require cessation of anticoagulation for a planned elective procedure.
Principal Investigators: Martha Louzada
Funding: London Multiple Myeloma Support Group
Design: Pilot open-label RCT to compare the efficacy and safety of Rivaroxaban or ASA in preventing venous or arterial thromboembolic events in patients with myeloma on Len-Dex based therapy
For more information:NCT03428373 https://clinicaltrials.gov/
Principal Investigators: Aurélien Delluc
Co-Investigators:
Mark Crowther (Hamilton)
Sébastien Miranda (Ottawa)
Alejandro Lazo-Langner (London)
Walter Agenda (Italy)
Funding: CanVECTOR Pilot
Design: Prospective pilot cohort study investigating treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban.
Principal Investigators: Jean Philippe Galanaud, Susan Kahn;
Funding: LEO Pharma
Design: RCT comparing 3-weeks of tinzaparin then DOAC vs DOAC alone for prevention of PTS in high-risk symptomatic DVT patients (Iliac vein or common femoral vein).
Principal Investigators: Rick Ikesaka, Marc Carrier
Funding: CanVECTOR Pilot
Design: Pilot double-blind placebo-controlled RCT (randomized clinical trial) investigating primary thromboprophylaxis with rivaroxaban in patients with malignancy and central venous catheters.